4.8 Article

Prooncogenic Factors miR-23b and miR-27b Are Regulated by Her2/Neu, EGF, and TNF-α in Breast Cancer

Journal

CANCER RESEARCH
Volume 73, Issue 9, Pages 2884-2896

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-2162

Keywords

-

Categories

Funding

  1. NIH [5R01CA115706]
  2. Susan G. Komen for the Cure [BCTR0600278]
  3. Louisiana Cancer Research Consortium
  4. state of Louisiana
  5. Department of Defense Breast Cancer Idea Award
  6. Developmental Research Award through MD Anderson's Breast Cancer SPORE
  7. Laura and John Arnold Foundation
  8. RGK Foundation
  9. Estate of C.G. Johnson, Jr.
  10. MD Anderson's core grant (Cancer Center Support Grant) from the NIH [CA016672]

Ask authors/readers for more resources

miRNAs (miR) are a critical class of small (21-25 nucleotides) noncoding endogenous RNAs implicated in gene expression regulation. We identified miR-23b and miR-27b as miRNAs that are highly upregulated in human breast cancer. We found that engineered knockdown of miR-23b and miR-27b substantially repressed breast cancer growth. Nischarin (NISCH) expression was augmented by knockdown of miR-23b as well as miR-27b. Notably, these miRNAs and Nischarin were inversely expressed in human breast cancers, underscoring their biologic relevance. We showed the clinical relevance of the expression of these miRNAs and showed that high expression of miR-23b and miR-27b correlates with poor outcome in breast cancer. Moreover, intraperitoneally delivered anti-miR-27b restored Nischarin expression and decreased tumor burden in a mouse xenograft model of human mammary tumor. Also, we report for the first time that HER2/neu (ERBB2), EGF, and TNF-apromote miR-23b/27b expression through the AKT/NF-kappa B signaling cascade. Nischarin was found to regulate miR-27b/23b expression through a feedback loop mechanism by suppressing NF-kappa B phosphorylation. Because anti-miR-27b compounds that suppress miR-27b inhibit tumor growth, the anti-miR-27b seems to be a good candidate for the development of new antitumor therapies. (C) 2013 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available